Sarepta Price Target Raised To $168 From $83 At Piper Jaffray
June 20, 2018 at 08:15 AM EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $168 from $83 after the company presented Phase I/II data on three Duchenne muscular dystrophy boys receiving its micro-dystrophin gene therapy.
